Abstract
Linezolid, a novel synthetic antibiotic compound with enhanced activity against Gram-positive infections, is at the center of much interest lately owing to the soaring prevalence of antibiotic-resistant Gram-positive bacteria. Since its inception, linezolid has been used successfully for the treatment of many different types of infections. Based on a number of clinical and pharmacokinetic trials, however, it seems that linezolid is particularly well suited to the treatment of skin and soft-tissue infections (SSTIs). Currently available evidence supports that the choice of linezolid should be considered as a valuable alternative, particularly for those cases where the patient presents with a complicated SSTI, has comorbid conditions or requires outpatient treatment. With serious adverse events being reported only in rare cases (mainly in those receiving longer courses of treatment) linezolid is furthermore considered to be a safe antibiotic agent for short therapeutic courses.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Notes
Modified with permission from Citation[87].